PMID- 16321826
OWN - NLM
STAT- MEDLINE
DCOM- 20060406
LR  - 20220331
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 47
IP  - 1
DP  - 2006 Jan
TI  - Prognostic relevance of CD56 expression in multiple myeloma: a study including 
      107 cases treated with high-dose melphalan-based chemotherapy and autologous stem 
      cell transplant.
PG  - 43-7
AB  - CD56 is a neural adhesion molecule and expressed in 70-80% cases of multiple 
      myeloma (MM). Lack of CD56 expression has shown to be a poor prognosis in MM 
      patients treated with conventional chemotherapy, but its prognostic relevance in 
      MM treated with high dose chemotherapy and autologous stem cell transplant (ASCT) 
      is not known. CD56 expression was evaluated by immunohistochemistry on bone 
      marrow paraffin embed specimens from 107 MM cases undergoing Melphalan-based high 
      dose therapy and ASCT. CD56 was expressed by the myeloma cells in 71% of the 
      patients. CD56 negative myeloma was associated with bone lesions (p = 0.032), but 
      there was no association with any other biological or genetic risk factors 
      including deletions 13q, p53 and IgH translocations, as evaluated by fluorescence 
      in situ hybridization (FISH). There was no significant difference between CD56 
      positive and CD56 negative myeloma for progression free or overall survival (p = 
      0.28 and p = 0.67, respectively). In contrast to reports of CD56 in myeloma 
      treated with conventional chemotherapy, CD56 negativity was not found to confer a 
      poor prognosis in these patients, suggesting Melphalan-based high-dose 
      chemotherapy and ASCT may overcome the adverse influence of CD56 negative 
      myeloma.
FAU - Chang, Hong
AU  - Chang H
AD  - Department of Laboratory Hematology, Princess Margaret Hospital/University Health 
      Network, University of Toronto, ON, Canada. hong.chang@uhn.on.ca
FAU - Samiee, Sara
AU  - Samiee S
FAU - Yi, Qi Long
AU  - Yi QL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (CD56 Antigen)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - CD56 Antigen/*biosynthesis/immunology
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Melphalan/*therapeutic use
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*immunology/*therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Time Factors
MH  - Transplantation, Autologous/methods
MH  - Treatment Outcome
EDAT- 2005/12/03 09:00
MHDA- 2006/04/07 09:00
CRDT- 2005/12/03 09:00
PHST- 2005/12/03 09:00 [pubmed]
PHST- 2006/04/07 09:00 [medline]
PHST- 2005/12/03 09:00 [entrez]
AID - M550664643878LG2 [pii]
AID - 10.1080/10428190500272549 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2006 Jan;47(1):43-7. doi: 10.1080/10428190500272549.